Results 251 to 260 of about 2,878,819 (307)

Therapeutic antibodies for the prevention and treatment of cancer. [PDF]

J Biomed Sci
Kumar M, Jalota A, Sahu SK, Haque S.
europepmc   +1 more source

Deep mutational learning for the selection of therapeutic antibodies resistant to the evolution of Omicron variants of SARS-CoV-2. [PDF]

Nat Biomed Eng
Frei L, Gao B, Han J, Taft JM, Irvine EB, Weber CR, Kumar RK, Eisinger BN, Ignatov A, Yang Z, Reddy ST.   +10 more
europepmc   +1 more source

Analysis of the Structure of 14 Therapeutic Antibodies Using Circular Dichroism Spectroscopy. [PDF]

Anal Chem
Bruque MG, Rodger A, Hoffmann SV, Jones NC, Aucamp J, Dafforn TR, Thomas ORT.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Designing antibodies as therapeutics

Cell, 2022
Antibody therapeutics are a large and rapidly expanding drug class providing major health benefits. We provide a snapshot of current antibody therapeutics including their formats, common targets, therapeutic areas, and routes of administration. Our focus is on selected emerging directions in antibody design where progress may provide a broad benefit ...
Paul J. Carter, Arvind Rajpal
openaire   +2 more sources

Therapeutic Antibodies

Current Molecular Medicine, 2004
Monoclonal antibodies had the lure of drugs very much since their first description. The ability to bind to a predetermined chemical structure stimulated the imagination of drug discoverers and developers. Nevertheless it took many years before a drug was registered which started to make good on the promise.
Bernd, Groner, Cord, Hartmann, Winfried, Wels   +2 more
openaire   +2 more sources

THERAPEUTIC MONOCLONAL ANTIBODIES

Rheumatology, 1995
Monoclonal antibodies have been used extensively over the last few years in clinical trials of rheumatoid arthritis (RA). Not only are they potential therapeutic agents, but they are also useful probes into the immunopathogenesis of RA. Anti-tumour necrosis factor alpha (TNF alpha) monoclonal antibodies have been shown to be clinically efficacious ...
E H, Choy, G S, Panayi, G H, Kingsley
openaire   +2 more sources

Therapeutic Antibodies: An Overview

2021
Polyclonal immunoglobulin (Ig) preparations have been used for several decades for treatment of primary and secondary immunodeficiencies and for treatment of some infections and intoxications. This has demonstrated the importance of Igs, also called antibodies (Abs) for prevention and elimination of infections.
openaire   +2 more sources

Human therapeutic antibodies

Current Opinion in Pharmacology, 2001
The development of genetic engineering technologies has today advanced to the point where the generation of high-affinity human antibodies against therapeutic targets is not a major hurdle. Rather, it is the selection of target molecules in, for example, cancer therapy that poses a challenge. Targets that are not merely passive acceptors but those that
C A, Borrebaeck, R, Carlsson
openaire   +2 more sources

Synthetic therapeutic antibodies

Nature Chemical Biology, 2006
Advances in selection technologies have sped up the process of generating antibodies with exquisitely tailored characteristics. In particular, synthetic antibody libraries, in which the antigen-binding sites are entirely man-made, have come of age and now rival or even exceed the potential of natural immune repertoires. Control over both library design
Sachdev S, Sidhu, Frederic A, Fellouse
openaire   +2 more sources

Antibody Therapeutics in Cancer

Science, 2013
In a relatively short period of time, monoclonal antibodies have entered the mainstream of cancer therapy. Their first use was as antagonists of oncogenic receptor tyrosine kinases, but today monoclonal antibodies have emerged as long-sought vehicles for the targeted delivery of potent chemotherapeutic agents and as powerful tools to manipulate ...
Mark X, Sliwkowski, Ira, Mellman
openaire   +2 more sources